HC Wainwright Says Talaris' Technology Unprecedented In Cell Therapy Space

HC Wainwright Says Talaris' Technology Unprecedented In Cell Therapy Space
  • HC Wainwright initiated coverage on Talaris Therapeutics Inc TALS with a Buy rating and a price target of $18.
  • Talaris leverages its novel “facilitated” allogeneic hematopoietic stem cell (Allo-HSCT) transplantation platform for solid organ transplantation, autoimmune diseases, and severe blood, immune and metabolic disorders. 
  • The facilitated Allo-HSCT attempts to unify two immune systems into one (chimerism) such that both the donor and recipient immune cells function harmoniously in the recipient. 
  • Earlier today, Talaris received a report of a patient death, which triggered a pre-specified, temporary stopping requirement and review by the FREEDOM-1 Data Monitoring Committee (DMC)
  • The analyst views the attributes of Talaris’ technology as unprecedented in the cell therapy space and holding potential for broad market adoption in kidney transplants and other indications.
  • If approved by the end of 2026, HC Wainwright expects FCR001 could achieve over $1 billion in sales in the U.S. by 2030, with significant room for upside growth in the succeeding years.
  • The analyst also notes investor concerns regarding treatment-related GvHD incidence and writes that physicians perceive mild Grade 2 GvHD as a recurring event in kidney transplant patients.
  • Price Action: TALS shares are down 44.63% at $1.34 on the last check Thursday.

Posted In: BriefsAnalyst ColorBiotechNewsPenny StocksHealth CarePrice TargetInitiationAnalyst RatingsMoversTrading IdeasGeneral